Literature DB >> 32504193

Clinical and serological characteristics of seronegative primary Sjögren's syndrome: a comparative study.

Veli Yazisiz1, Bengisu Aslan2, Funda Erbasan2, İsmail Uçar2, Tahir Saygin Öğüt2, Mustafa Ender Terzioğlu2.   

Abstract

OBJECTIVES: This study compared the clinical and serological characteristics of seronegative and seropositive primary Sjögren syndrome (pSS) and examined whether current classification criteria for pSS cover seronegative pSS.
METHODS: The study group comprised 375 patients (341 women and 34 men) diagnosed with pSS. A clinical diagnosis by an expert rheumatologist was considered the "gold standard" for the diagnosis of pSS. The clinical and serological characteristics of the patients were retrospectively collected from hospital medical files.
RESULTS: Fifty-eight of the 375 pSS patients (15.5%) were seronegative for ANA, RF, anti-Ro, and anti-La autoantibodies. Seronegative pSS was diagnosed based on lymphocytic infiltrations in lip biopsy samples. There were no statistically significant differences in terms of patient age, age at diagnosis, sex distribution, clinical features, and laboratory findings between seronegative and seropositive pSS. The frequency of hypergammaglobulinemia was higher in seropositive pSS. The 2016 ACR/ULAR criteria best covered most seronegative pSS cases (84.5%). For seronegative pSS, the agreement between the 2002 AECG, 2012 ACR, and 2016 ACR/EULAR criteria was relatively low.
CONCLUSIONS: The clinical features of seronegative pSS (i.e., a lack of four autoantibodies in serum) were similar to those of seropositive pSS. The current classification criteria for pSS should not be used in the diagnosis of seronegative pSS, as the agreement between the different sets of criteria was low, and some patients fell outside the classification. Further clinical and laboratory studies are needed to identify the features that distinguish seronegative pSS. Key Points • Approximately 15% of the pSS patients were seronegative for ANA, RF, anti-Ro, and anti-La autoantibodies. • Seronegative pSS was diagnosed based on lymphocytic infiltrations in lip biopsy samples. • The clinical features of seronegative pSS were similar to those of seropositive pSS. • The current classification criteria for pSS should not be used in the diagnosis of seronegative patients, as the agreement between the different sets of criteria was low, and some patients fell outside the classification.

Entities:  

Keywords:  Anti-La; Anti-Ro; Antinuclear antibody (ANA); Classification criteria; Rheumatoid factor (RF); Sjögren’s syndrome

Mesh:

Substances:

Year:  2020        PMID: 32504193     DOI: 10.1007/s10067-020-05154-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  27 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  Survival analysis of patients with Sjögren's syndrome in Turkey: a tertiary hospital-based study.

Authors:  Veli Yazisiz; Mesut Göçer; Funda Erbasan; İsmail Uçar; Bengisu Aslan; Şuayp Oygen; Edip Gökalp Gök; Mustafa Ender Terzioğlu
Journal:  Clin Rheumatol       Date:  2019-09-25       Impact factor: 2.980

3.  Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome.

Authors:  F N Skopouli; U Dafni; J P Ioannidis; H M Moutsopoulos
Journal:  Semin Arthritis Rheum       Date:  2000-04       Impact factor: 5.532

Review 4.  Primary Sjögren's Syndrome.

Authors:  Xavier Mariette; Lindsey A Criswell
Journal:  N Engl J Med       Date:  2018-03-08       Impact factor: 91.245

5.  Active immunological profile is associated with systemic Sjögren's syndrome.

Authors:  Clothilde Martel; Guillaume Gondran; David Launay; Fabrice Lalloué; Sylvain Palat; Marc Lambert; Kim Ly; Veronique Loustaud-Ratti; Holly Bezanahary; Eric Hachulla; Marie Odile Jauberteau; Elisabeth Vidal; Pierre Yves Hatron; Anne Laure Fauchais
Journal:  J Clin Immunol       Date:  2011-07-09       Impact factor: 8.317

Review 6.  Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution.

Authors:  Luca Quartuccio; Chiara Baldini; Elena Bartoloni; Roberta Priori; Francesco Carubbi; Laura Corazza; Alessia Alunno; Serena Colafrancesco; Nicoletta Luciano; Roberto Giacomelli; Roberto Gerli; Guido Valesini; Stefano Bombardieri; Salvatore De Vita
Journal:  Autoimmun Rev       Date:  2015-07-08       Impact factor: 9.754

Review 7.  Autoantibodies in Sjögren's syndrome: clinical presentation and regulatory mechanisms.

Authors:  Athanasios G Tzioufas; Ioanna P Tatouli; Haralampos M Moutsopoulos
Journal:  Presse Med       Date:  2012-07-25       Impact factor: 1.228

8.  Diagnostic performance of minor salivary gland biopsy, serological and clinical data in Sjögren's syndrome: a retrospective analysis.

Authors:  Veli Yazisiz; Ali Berkant Avci; Funda Erbasan; Evren Kiriş; Ender Terzioğlu
Journal:  Rheumatol Int       Date:  2008-09-18       Impact factor: 2.631

Review 9.  Subgroups of Sjögren syndrome patients according to serological profiles.

Authors:  Vasiliki-Kalliopi Bournia; Panayiotis G Vlachoyiannopoulos
Journal:  J Autoimmun       Date:  2012-05-08       Impact factor: 7.094

10.  2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts.

Authors:  Caroline H Shiboski; Stephen C Shiboski; Raphaèle Seror; Lindsey A Criswell; Marc Labetoulle; Thomas M Lietman; Astrid Rasmussen; Hal Scofield; Claudio Vitali; Simon J Bowman; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2016-10-26       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.